SCHEMBL1019932

SCHEMBL1019932

CC(C)(C)NC(=O)c1cccc(CN2CCN(C(=O)c3ccc(NC(=O)NCCc4ccc5c(c4)OCO5)c(F)c3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.52
KMT2A Q03164 5/20 0.52
L3MBTL1 Q9Y468 2/20 0.48
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
CHRM3 P20309 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
KDM4E B2RXH2 2/20 0.46
FABP1 P07148 1/20 0.44
FABP6 P51161 1/20 0.44
LMNA P02545 1/20 0.44
CCR6 P51684 1/20 0.44
USP2 O75604 1/20 0.44
PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019026 0.89 CCR3 (0.47) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1019575 0.85 MEN1 (0.42) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1018649 0.85 MEN1 (0.42) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1019141 0.84 ACKR3 (0.43) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1018580 0.84 MEN1 (0.41) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL4297672 0.84 KMT2A (0.46) MEN1KMT2AL3MBTL1SMN1; SMN2LMNA
SCHEMBL1019162 0.84 MEN1 (0.44) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3763907 0.83 THRB (0.42) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1018852 0.82 MEN1 (0.42) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL1020048 0.82 MEN1 (0.42) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 MEN1 4243/4885KMT2A 4268/4885L3MBTL1 4616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.